End Cash: The amount of cash held by the company for the given period.
NewAmsterdam Pharma Company N.V. (NAMS) had End Cash of $748.42M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$2.98M |
|
$-39.53M |
|
-- |
|
$2.98M |
|
$71.90M |
|
$-68.92M |
|
$29.40M |
|
$-39.53M |
|
$-39.53M |
|
$-39.53M |
|
$-39.53M |
|
$-39.53M |
|
$-39.53M |
|
$-68.92M |
|
$-68.87M |
|
116.12M |
|
116.12M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$817.30M |
|
$0.24M |
|
$1.11M |
|
$818.41M |
|
$40.91M |
|
-- |
|
$0.14M |
|
$41.05M |
|
$777.36M |
|
$776.86M |
|
$777.36M |
|
112.17M |
|
| Cash Flow Statement Financials | |
$-36.47M |
|
$2.85M |
|
$6.52M |
|
$771.74M |
|
|
End Cash |
$748.42M |
$-23.32M |
|
$15.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-2314.47% |
|
-2314.47% |
|
-- |
|
-1327.30% |
|
-1327.30% |
|
$-36.48M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-5.08% |
|
-5.09% |
|
-4.83% |
|
-5.08% |
|
$6.93 |
|
$-0.31 |
|
$-0.31 |
|